These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 10767354)
1. Cellular kinetics and expression of bcl-2 and p53 in ductal carcinoma of the breast. Megha T; Ferrari F; Arcuri F; Lalinga AV; Lazzi S; Cardone C; Cevenini G; Leoncini L; Tosi P Oncol Rep; 2000; 7(3):473-8. PubMed ID: 10767354 [TBL] [Abstract][Full Text] [Related]
2. p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin. Megha T; Ferrari F; Benvenuto A; Bellan C; Lalinga AV; Lazzi S; Bartolommei S; Cevenini G; Leoncini L; Tosi P J Clin Pathol; 2002 Jun; 55(6):461-6. PubMed ID: 12037031 [TBL] [Abstract][Full Text] [Related]
3. Correlation between the expression of apoptosis-related bcl-2 and p53 oncoproteins and the carcinogenesis and progression of breast carcinomas. Zhang GJ; Kimijima I; Abe R; Kanno M; Katagata N; Hara K; Watanabe T; Tsuchiya A Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2329-35. PubMed ID: 9815631 [TBL] [Abstract][Full Text] [Related]
4. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers. Rehman S; Crow J; Revell PA Pathol Oncol Res; 2000; 6(4):256-63. PubMed ID: 11173657 [TBL] [Abstract][Full Text] [Related]
5. Apoptosis in ductal carcinoma in situ of the breast. Moreno A; Figueras A; Lloveras B; Escobedo A; Griera E; Sierra A; Fabra A Breast J; 2001; 7(4):245-8. PubMed ID: 11678802 [TBL] [Abstract][Full Text] [Related]
6. HER2 as a prognostic factor in breast cancer. Ménard S; Fortis S; Castiglioni F; Agresti R; Balsari A Oncology; 2001; 61 Suppl 2():67-72. PubMed ID: 11694790 [TBL] [Abstract][Full Text] [Related]
7. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium. Ioffe OB; Papadimitriou JC; Drachenberg CB Hum Pathol; 1998 Oct; 29(10):1150-9. PubMed ID: 9781657 [TBL] [Abstract][Full Text] [Related]
8. Elevated expression of the tumor suppressing protein p53 is associated with the presence of mouse mammary tumor-like env gene sequences (MMTV-like) in human breast cancer. Lawson JS; Tran DD; Ford C; Rawlinson WD Breast Cancer Res Treat; 2004 Sep; 87(1):13-7. PubMed ID: 15377846 [TBL] [Abstract][Full Text] [Related]
9. Analysis of bcl-2 in sporadic breast carcinoma. Dueñas-González A; Abad-Hernández MM; Cruz-Hernández JJ; González-Sarmiento R Cancer; 1997 Dec; 80(11):2100-8. PubMed ID: 9392332 [TBL] [Abstract][Full Text] [Related]
10. Alterations of p53, Bcl-2, and hMSH2 protein expression in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas in the upper Egypt. Hussein MR; Ismael HH Cancer Biol Ther; 2004 Oct; 3(10):983-8. PubMed ID: 15467428 [TBL] [Abstract][Full Text] [Related]
11. [Correlation between apoptotic index, bcl-2 protein expression and progression and prognosis in breast carcinoma]. Zhang GJ; Kimijima I; Watanabe T; Kanno M; Sagara H; Furukawa Y; Tsuchiya A; Abe R Gan To Kagaku Ryoho; 1998 Apr; 25 Suppl 3():415-21. PubMed ID: 9589045 [TBL] [Abstract][Full Text] [Related]
12. bcl-2 expression in the spectrum of preinvasive breast lesions. Siziopikou KP; Prioleau JE; Harris JR; Schnitt SJ Cancer; 1996 Feb; 77(3):499-506. PubMed ID: 8630957 [TBL] [Abstract][Full Text] [Related]
13. Expression and mutational status of RON in neoplastic lesions of the breast: analysis of MSP/RON signaling in ductal carcinoma in situ and invasive ductal carcinoma. Ren X; Daa T; Yada N; Kashima K; Fujitomi Y; Yokoyama S APMIS; 2012 May; 120(5):358-67. PubMed ID: 22515290 [TBL] [Abstract][Full Text] [Related]
14. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast]. Yang M; Xu SP; Ao QL Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534 [TBL] [Abstract][Full Text] [Related]
15. The relationship between expression of p53/Bcl-2 and histopathological criteria in breast invasive ductal carcinomas. Gursan N; Karakök M; Sari I; Gursan MS Int J Clin Pract; 2001 Nov; 55(9):589-90. PubMed ID: 11770353 [TBL] [Abstract][Full Text] [Related]
16. Analysis of p53 mutations in cells taken from paraffin-embedded tissue sections of ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Keohavong P; Gao WM; Mady HH; Kanbour-Shakir A; Melhem MF Cancer Lett; 2004 Aug; 212(1):121-30. PubMed ID: 15246568 [TBL] [Abstract][Full Text] [Related]
17. Evidence of significant apoptosis in poorly differentiated ductal carcinoma in situ of the breast. Gandhi A; Holland PA; Knox WF; Potten CS; Bundred NJ Br J Cancer; 1998 Sep; 78(6):788-94. PubMed ID: 9743302 [TBL] [Abstract][Full Text] [Related]
18. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women. Rodrigues NA; Dillon D; Carter D; Parisot N; Haffty BG Cancer; 2003 Mar; 97(6):1393-403. PubMed ID: 12627502 [TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling of tumour epithelial and stromal compartments during breast cancer progression. Vargas AC; McCart Reed AE; Waddell N; Lane A; Reid LE; Smart CE; Cocciardi S; da Silva L; Song S; Chenevix-Trench G; Simpson PT; Lakhani SR Breast Cancer Res Treat; 2012 Aug; 135(1):153-65. PubMed ID: 22718308 [TBL] [Abstract][Full Text] [Related]
20. Terminal uridine nick end labelling and mitosis in breast carcinoma. Correlation with tumor grade and p53 overexpression. Dey P; Luthra UK; George SS; Haji BI; George J Anal Quant Cytol Histol; 2001 Feb; 23(1):27-30. PubMed ID: 11233740 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]